The NASDAQ Stock Market announced that it will delist the common stock of Genitope Corporation. Genitope Corporation's stock was suspended on August 18, 2008 and has not traded on NASDAQ since that time. NASDAQ will file a Form 25 with the Securities and Exchange Commission to complete the delisting. The delisting becomes effective ten days after the Form 25 is filed.

Genitope Corporation announced that, on August 7, 2008, it received a staff determination letter from The NASDAQ Stock Market (NASDAQ) formally notifying Genitope that it has not regained compliance with the minimum $1.00 per share bid price requirement for continued inclusion on the NASDAQ Global Market under Marketplace Rule 4450(a)(5) and that, unless appealed, trading in Genitope’s common stock will be suspended. Genitope does not currently intend to appeal this determination. As a result, trading of Genitope’s common stock will be suspended at the opening of business on August 18, 2008 and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove Genitope’s securities from listing and registration on The NASDAQ Stock Market. NASDAQ has also advised Genitope that Genitope’s common stock will not be immediately eligible to trade on the OTC Bulletin Board or in the “Pink Sheets.” However, Genitope’s securities may become eligible if a market maker makes application to register in and quote the security in accordance with SEC Rule 15c2-11 and if such application is cleared. Only a market maker, not Genitope, may make this application.

On 08/12/2008, Genitope Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.